Business
Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting
Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nOncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting\nCanada NewsWire\nCALGARY, Dec. 6, 2016\n\n\n\n-- Preliminary data suggest evidence of activity and that the treatment combination was well tolerated -- \n\n\n\nCALGARY, Dec. 6, 2016 /CNW/ - Oncolytics Biotech® Inc. (\"Oncolytics\" or the \"Company\") (TSX:ONC) (OTCQX:ONCYF) today announced that Dr. Kevin Kelly and colleagues made a poster presentation at the 58th American Society of Hematology (\"ASH\") Annual Meeting. The poster presentation, titled \"Oncolytic Reovirus Immune Priming: A Phase Ib Study of REOLYSIN® with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma,\" provides initial findings from the Company's REO 019 Phase Ib trial. The ASH Annual Meeting runs from December 3rd to 6th in San Diego, CA.\n\nThe study is a two-stage open-label Phase Ib trial of adult patients with relapsed or refractory multiple myeloma following at least one line of therapy. This study was designed to evaluate tolerability, to confirm that the addition of REOLYSIN® to bortezomib increases endoplasmic reticulum stress and death of myeloma cells (as shown in preclinical models) and to document pharmacodynamic effects as part of the characterization of the mechanism(s) of action of REOLYSIN® in multiple myeloma. Kevin Kelly, M.D., Ph.D. of the Keck School of Medicine of the University of Southern California (USC), is the principal investigator.\n\n\"The combination of REOLYSIN®, bortezomib and dexamethasone was well-tolerated in these heavily pre-treated patients, even in those who had been previously exposed to bortezomib,\" said Dr. Kevin Kelly. \"Preliminary evidence ...